Blueprint
FORM
6-K
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
Report
of Foreign Issuer
Pursuant to Rule
13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of October 2016
Commission File
Number: 001-11960
AstraZeneca
PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge CB2
0AA
United
Kingdom
Indicate by check
mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F.
Form
20-F X
Form
40-F __
Indicate by check
mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1):
Indicate by check
mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7): ______
Indicate by check
mark whether the registrant by furnishing the information contained
in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange
Act of 1934.
Yes __ No
X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule
12g3-2(b): 82-_____________
AstraZeneca
PLC
INDEX
TO EXHIBITS
1. AZ DIVESTS RIGHTS TO RHINOCORT AQUA
OUTSIDE US dated 07th October 2016
This announcement contains
inside
information
7 October 2016 07:00
ASTRAZENECA ENTERS AGREEMENT WITH
CILAG GMBH INTERNATIONAL TO DIVEST RIGHTS TO RHINOCORT
AQUA
OUTSIDE THE US
AstraZeneca today announced that it has entered into an agreement
with Cilag GmbH International, an affiliate of Johnson &
Johnson, for the divestment of the rights to Rhinocort Aqua outside the US.
Rhinocort Aqua is a nasal spray indicated for allergic and
non-allergic rhinitis (inflammation of the inside of the
nose), and for the treatment of nasal polyps (swelling of the
nasal lining). The active ingredient is the
anti-inflammatory medicine budesonide.
Mark
Mallon, Executive Vice President, Global Product & Portfolio
Strategy at AstraZeneca, said: "This agreement allows us to
concentrate our efforts in Respiratory as one of our three
strategic therapy areas, on transforming the treatment of asthma
and COPD, where budesonide remains a key component of our marketed
as well as pipeline medicines."
Financial considerations
The
agreement is subject to customary closing conditions and is
expected to complete in the fourth quarter of 2016. As AstraZeneca
will not maintain a significant ongoing interest in Rhinocort Aqua, the $330 million
payment received from Cilag GmbH International upon completion of
the transaction will be recognised as Other Operating Income in the
Company's financial statements. The transaction does not include
the transfer of any AstraZeneca employees or facilities and does
not impact the Company's financial guidance for 2016.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that
focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of diseases in
three therapy areas - Respiratory, Cardiovascular &
Metabolic Diseases, and
Oncology. The Company is also selectively active in Neuroscience
and Autoimmunity. AstraZeneca operates in over 100 countries and
its innovative medicines are used by millions of patients
worldwide. For more information please visit: www.astrazeneca.com
CONTACTS
|
Media Enquiries
|
|
|
|
Neil
Burrows
|
UK/Global
|
+44 203
749 5637
|
|
Vanessa
Rhodes
|
UK/Global
|
+44 203
749 5736
|
|
Karen
Birmingham
|
UK/Global
|
+44 203
749 5634
|
|
Rob
Skelding
|
UK/Global
|
+44 203
749 5821
|
|
Jacob
Lund
|
Sweden
|
+46
8 553 260 20
|
|
Michele
Meixell
|
US
|
+1 302
885 2677
|
|
Investor Relations
|
|
|
|
UK
|
|
|
|
Thomas
Kudsk Larsen
|
|
+44 203
749 5712
|
|
Craig
Marks
|
Finance,
Fixed Income, M&A
|
+44
7881 615 764
|
|
Nick
Stone
|
Respiratory
|
+44 203
749 5716
|
|
Henry
Wheeler
|
Oncology
|
+44 203
749 5797
|
|
Christer
Gruvris
|
Neuroscience
& Autoimmunity
|
+44 203
749 5711
|
|
US
|
|
|
|
Lindsey
Trickett
|
Cardiovascular
& Metabolic Diseases
|
+1 240
543 7970
|
|
Mitchell
Chan
|
Oncology
|
+1 240
477 3771
|
|
Toll-free
|
|
+1 866
381 7277
|
Adrian
Kemp
Company
Secretary
AstraZeneca
PLC
-ENDS-
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the Registrant
has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
AstraZeneca
PLC
|
Date:
07 October 2016
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|